COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Durom(R) Hip Resurfacing System Multicenter Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00746616
Recruitment Status : Completed
First Posted : September 4, 2008
Last Update Posted : April 10, 2013
Information provided by (Responsible Party):
Zimmer Biomet

Brief Summary:
The purpose of the study is to gather clinical information on the safety and efficacy of the resurfacing devices in the young, active patient with advanced hip disease. Study enrollment has been temporarily suspended due to a change in the surgical technique.

Condition or disease Intervention/treatment Phase
Advanced Hip Disease Device: Durom Hip Resurfacing System Phase 3

Detailed Description:
Safety will be evaluated based on the frequency and incidence of any device related adverse events or unanticipated adverse device events. The efficacy will be measured by comparing the overall functional performance based on the Harris Hip Score, implant survivorship, and radiographic parameters, including radiolucencies, osteolysis, stem subsidence, cup migration, and change in cup angle and a change in the femoral shaft angle.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Durom(R) Hip Resurfacing System Multicenter Trial
Study Start Date : June 2007
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Arm Intervention/treatment
Experimental: 1
Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
Device: Durom Hip Resurfacing System
Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
Other Name: Hip Reserfacing

Primary Outcome Measures :
  1. Device Survival [ Time Frame: All post-op visits until last patient enrolled reaches 2 year follow-up ]

Secondary Outcome Measures :
  1. Efficacy [ Time Frame: 6 month post-op and annually until last patient reaches 2 year follow-up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient selection without bias to race or gender
  • Patient is greater than or equal to 18 and less than or equal to 65 years of age.
  • Female patients only:

    • actively practicing a contraceptive method, or
    • surgically sterilized, or
    • post-menopausal
  • Pre-operative Harris Hip Score less than or equal to 70.
  • Primary surgical hip candidate, suffering from hip pain and/or disability due to degenerative joint disease (inflammatory or non-inflammatory), based on physical examination and history, including the following diagnosis:

    • non-inflammatory degenerative joint disease (NIDJD), e.g. avascular necrosis or osteoarthritis
    • inflammatory joint disease (IJD), e.g. rheumatoid arthritis
  • Patient is willing and able to cooperate in prescribed post-operative therapy.
  • Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.
  • Patient has participated in the Informed Consent process and has signed and IRB approved Informed Consent.

Exclusion Criteria:

  • Patient with an acute, chronic, local or systemic infection.
  • Patient who is skeletally immature.
  • Patient with a severe muscular, neural or vascular disease that endangers the involved extremity.
  • Patient with an insufficient acetabular or femoral bone stock in which good anchorage of the implants are unlikely or impossible, including but not limited to:

    • patient with severe osteopenia
    • patients with a family history of severe osteoporosis or osteopenia
    • patients with osteonecrosis or avascular necrosis (AVN) with > 50% involvement of the femoral head (regardless of FICAT grade)
    • patients with multiple cysts of the femoral head > 1cm
  • Patient with total or partial absence of the muscular of ligamentous apparatus.
  • Patient has known moderate to severe renal insufficiency.
  • Patient with a known clinical condition which may interfere with patient outcome, including but not limited to:

    • immuno-compromised conditions (AIDS),
    • organ transplant recipient,
    • high doses of corticosteroids etc
  • Patient who is severely overweight (BMI >40)
  • Operative (ipsilateral) Hip: Patient has a total prosthetic hip replacement device, surface arthroplasty or endoprosthesis.
  • Contralateral Hip: Patient has had hip replacement, surface arthroplasty or endoprosthesis, within the past 12 months, unless already enrolled in this investigational study.
  • Patient who is:

    • a prisoner
    • mentally incompetent
    • a known alcohol or drug abuser
    • anticipated to be non-compliant
  • Patient who has participated in a study of any other investigational device (drug, device or biologic) within the past 12 months. Exception: previous enrollment in the Durom Hip Resurfacing System clinical study.
  • Patient has a known allergy to one of the constituents of the implant, e.g. cobalt, chromium, nickel, etc.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00746616

Layout table for location information
United States, Colorado
Colorado Joint Replacement
Denver, Colorado, United States, 80210
United States, New York
Syracuse Orthopedic Specialists
De Witt, New York, United States, 13214
United States, Oklahoma
Eastern Oklahoma Orthopedic Center
Tulsa, Oklahoma, United States, 74136
United States, Pennsylvania
PENN Orthopedics
Philadelphia, Pennsylvania, United States, 19107
United States, Texas
Texas Hip and Knee
Fort Worth, Texas, United States, 76104
Sponsors and Collaborators
Zimmer Biomet
Layout table for additonal information
Responsible Party: Zimmer Biomet Identifier: NCT00746616    
Other Study ID Numbers: 06-100
First Posted: September 4, 2008    Key Record Dates
Last Update Posted: April 10, 2013
Last Verified: April 2013
Keywords provided by Zimmer Biomet:
Total Hip Arthroplasty,
Acetabular Cup,
Hip Resurfacing